BNTXBioNTech SE

Nasdaq biontech.de


$ 83.36 $ -0.24 (-0.29 %)    

Wednesday, 26-Jun-2024 10:54:13 EDT
QQQ $ 479.88 $ 0.27 (0.06 %)
DIA $ 390.03 $ -0.08 (-0.02 %)
SPY $ 544.24 $ 0.65 (0.12 %)
TLT $ 93.27 $ -0.29 (-0.31 %)
GLD $ 212.63 $ -1.56 (-0.73 %)
$ 84.38
$ 83.60
$ 83.00 x 122
$ 0.00 x 0
$ 83.05 - $ 83.63
$ 83.72 - $ 125.83
606,900
na
20.06M
$ 0.07
$ 0.02
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
No Data found
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 hc-wainwright--co-reiterates-buy-on-biontech-maintains-113-price-target

HC Wainwright & Co. analyst Robert Burns reiterates BioNTech (NASDAQ:BNTX) with a Buy and maintains $113 price target.

 gamestop-and-first-solar-were-among-the-10-biggest-large-cap-losers-last-week-june-16-june-22-are-these-in-your-portfolio

10 worst-performing large-cap stocks last week: GME, ENPH, ALB, BNTX, ALGN, FLSR, BALL, MBLY, BLD, JBL. Are they in your portfo...

 covid-19-pharma-stars-continue-their-quest-to-set-new-standards-in-cancer-treatment

AstraZeneca PLC (NASDAQ: AZN) kicked off the week by receiving approval from the U.S. Food and Drug Administration for its bloc...

 why-is-pfizer-partner-biontech-stock-trading-lower-on-monday

BioNTech partner MediLink Therapeutics faces a partial clinical hold from the FDA on the Phase 1 trial of BNT326/YL202 for adva...

 biontech-partner-medilink-therapeutics-says-fda-has-placed-partial-clinical-hold-on-phase-1-trial-of-bnt326yl202-for-heavily-pre-treated-advanced-or-metastatic-egfr-mutated-non-small-cell-lung-cancer-or-hrher2-negative-breast-cancer-6k

The partial hold affects the enrollment of new patients in the trial in the U.S.  The FDA has shared with MediLink concerns th...

Core News & Articles

- Reuters

 hc-wainwright--co-reiterates-buy-on-biontech-maintains-113-price-target

HC Wainwright & Co. analyst Robert Burns reiterates BioNTech (NASDAQ:BNTX) with a Buy and maintains $113 price target.

 moderna-seeks-fda-approval-for-updated-covid-19-shot-for-upcoming-season

Moderna has submitted an FDA application for its 2024-2025 Spikevax formula, targeting the prevalent SARS-CoV-2 variant JN.1.

Core News & Articles

- Reuters

Core News & Articles

- Bloomberg

Core News & Articles

https://globalnews.ca/news/10547712/bird-flu-death-mexico-h5n2/#:~:text=It%20started%20on%20April%2017,to%20complications%20of%...

Core News & Articles

- Bloomberg

Core News & Articles

- Reuters

 whats-going-on-with-novavax-stock

Novavax, Inc. shares are trading higher Wednesday, and the stock is up by more than 300% over the past month. Here's a look...

Core News & Articles

- Reuters

 hc-wainwright--co-reiterates-buy-on-biontech-maintains-113-price-target

HC Wainwright & Co. analyst Robert Burns reiterates BioNTech (NASDAQ:BNTX) with a Buy and maintains $113 price target.